Columbia News Updates

DelveInsight’s “Gastroenteropancreatic Neuroendocrine Tumor Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Gastroenteropancreatic Neuroendocrine Tumor, historical and forecasted epidemiology as well as the Gastroenteropancreatic Neuroendocrine Tumor market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Gastroenteropancreatic Neuroendocrine Tumor market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastroenteropancreatic Neuroendocrine Tumor Market Forecast

Some of the key facts of the Gastroenteropancreatic Neuroendocrine Tumor Market Report: 

• The Gastroenteropancreatic Neuroendocrine Tumor market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In September 2023, Novartis revealed that the Phase III NETTER-2 trial involving LUTATHERA achieved its primary goal. When used as a first-line treatment alongside long-acting octreotide, LUTATHERA showcased a notable enhancement in progression-free survival (PFS) among patients with newly diagnosed somatostatin receptor (SSTR)-positive, Grade 2 and 3, advanced gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs).
• In August 2023, Exelixis disclosed encouraging findings from the Phase III CABINET pivotal trial assessing cabozantinib in the treatment of advanced pancreatic and extra-pancreatic neuroendocrine tumors.
• GEP NETs constitute the predominant subtype of NETs, accounting for 50–70% of all cases.
• According to Masui et al. (2020), the age-adjusted overall incidence rate of gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan was 3.53 per 100,000 individuals. Neuroendocrine carcinomas (NECs) were predominant among NENs found in the esophagus or lungs, whereas grade 1 neuroendocrine tumors (NETs) were more prevalent in the duodenum, ileum, appendix, and rectum.
• Among the 15,222 NET cases diagnosed between 2013 and 2015, according to Genus et al. (2019), 50,7% had GEP-NENs; this patient cohort comprised both NETs and NECs, with the latter accounting for 37% of all cases
• Of the 837 GEP NETcases identified in Spain between 2001 and 2008, 1.7% were classified as poorly differentiated tumors, according to Garcia-Carbonero et al. (2010). The percentage of cases with probable gastrointestinal origin net tumors that were small intestinal, pancreatic, and unknown primary were, respectively, 55%, 36.3%, and 9.1%
• Key Gastroenteropancreatic Neuroendocrine Tumor Companies: ITM Isotope Technologies Munich, Camurus, RayzeBio, Merck Sharp & Dohme, Ipsen, Advanced Accelerator, Jiangsu HengRui Medicine, Camurus AB, Novartis, Tarveda Therapeutics, Progenics Pharmaceuticals, Pharmacyclics, and others
• Key Gastroenteropancreatic Neuroendocrine Tumor Therapies: ITM-11, CAM2029, RYZ101, Lanreotide, arginine, lysine, Temozolomide (TMZ), Lutetium (177Lu) Oxodotreotide Injection, CAM2029, Everolimus, PEN-221, Lutathera, Ibrutinib, and others
• The Gastroenteropancreatic Neuroendocrine Tumor epidemiology based on gender analyzed that the incidence of functional GEP-NET is more than that of nonfunctional GEP-NET in the United States
• The Gastroenteropancreatic Neuroendocrine Tumor market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastroenteropancreatic Neuroendocrine Tumor pipeline products will significantly revolutionize the Gastroenteropancreatic Neuroendocrine Tumor market dynamics.

Gastroenteropancreatic Neuroendocrine Tumor Overview

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a type of cancer that originates in the neuroendocrine cells of the gastrointestinal (GI) tract and pancreas. These tumors can develop in various parts of the digestive system, including the stomach, intestines, pancreas, appendix, and rectum. 

Get a Free sample for the Gastroenteropancreatic Neuroendocrine Tumor Market Report:

https://www.delveinsight.com/report-store/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market

Gastroenteropancreatic Neuroendocrine Tumor Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Gastroenteropancreatic Neuroendocrine Tumor Epidemiology Segmentation:

The Gastroenteropancreatic Neuroendocrine Tumor market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Gastroenteropancreatic Neuroendocrine Tumor
• Prevalent Cases of Gastroenteropancreatic Neuroendocrine Tumor by severity
• Gender-specific Prevalence of Gastroenteropancreatic Neuroendocrine Tumor
• Diagnosed Cases of Episodic and Chronic Gastroenteropancreatic Neuroendocrine Tumor

Download the report to understand which factors are driving Gastroenteropancreatic Neuroendocrine Tumor epidemiology trends @ Gastroenteropancreatic Neuroendocrine Tumor Epidemiology Forecast

Gastroenteropancreatic Neuroendocrine Tumor Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastroenteropancreatic Neuroendocrine Tumor market or expected to get launched during the study period. The analysis covers Gastroenteropancreatic Neuroendocrine Tumor market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gastroenteropancreatic Neuroendocrine Tumor Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Gastroenteropancreatic Neuroendocrine Tumor Therapies and Key Companies

• ITM-11: ITM Isotope Technologies Munich
• CAM2029: Camurus
• RYZ101: RayzeBio
• Lanreotide: Merck Sharp & Dohme
• arginine/lysine: Advanced Accelerator
• Temozolomide (TMZ): Ipsen
• Lutetium (177Lu) Oxodotreotide Injection: Jiangsu HengRui Medicine
• RYZ101: RayzeBio, Inc.
• CAM2029: Camurus AB
• Everolimus: Novartis
• PEN-221: Tarveda Therapeutics
• Lutathera: Progenics Pharmaceuticals
• Ibrutinib: Pharmacyclics

Discover more about therapies set to grab major Gastroenteropancreatic Neuroendocrine Tumor market share @ Gastroenteropancreatic Neuroendocrine Tumor Treatment Market 

Gastroenteropancreatic Neuroendocrine Tumor Market Strengths

• GEP-NETs are often diagnosed at an early stage due to the hormonal symptoms they produce, allowing for timely intervention and better outcomes. 
• Treatment of GEP-NETs involves a multidisciplinary team of specialists, including oncologists, surgeons, and endocrinologists, which enhances the overall management of the disease.

Gastroenteropancreatic Neuroendocrine Tumor Market Opportunities

• Continued research and development in targeted therapies, such as somatostatin analogs and molecular inhibitors, provide opportunities for more effective and personalized treatment approaches. 
• Participation in clinical trials can lead to the discovery of new treatment modalities and contribute to the improvement of patient outcomes.

Scope of the Gastroenteropancreatic Neuroendocrine Tumor Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Gastroenteropancreatic Neuroendocrine Tumor Companies: ITM Isotope Technologies Munich, Camurus, RayzeBio, Merck Sharp & Dohme, Ipsen, Advanced Accelerator, Jiangsu HengRui Medicine, Camurus AB, Novartis, Tarveda Therapeutics, Progenics Pharmaceuticals, Pharmacyclics, and others
• Key Gastroenteropancreatic Neuroendocrine Tumor Therapies: ITM-11, CAM2029, RYZ101, Lanreotide, arginine, lysine, Temozolomide (TMZ), Lutetium (177Lu) Oxodotreotide Injection, CAM2029, Everolimus, PEN-221, Lutathera, Ibrutinib, and others
• Gastroenteropancreatic Neuroendocrine Tumor Therapeutic Assessment: Gastroenteropancreatic Neuroendocrine Tumor current marketed and Gastroenteropancreatic Neuroendocrine Tumor emerging therapies
• Gastroenteropancreatic Neuroendocrine Tumor Market Dynamics: Gastroenteropancreatic Neuroendocrine Tumor market drivers and Gastroenteropancreatic Neuroendocrine Tumor market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Gastroenteropancreatic Neuroendocrine Tumor Unmet Needs, KOL’s views, Analyst’s views, Gastroenteropancreatic Neuroendocrine Tumor Market Access and Reimbursement 

To know more about Gastroenteropancreatic Neuroendocrine Tumor companies working in the treatment market, visit @ Gastroenteropancreatic Neuroendocrine Tumor Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Gastroenteropancreatic Neuroendocrine Tumor Market Report Introduction

2. Executive Summary for Gastroenteropancreatic Neuroendocrine Tumor

3. SWOT analysis of Gastroenteropancreatic Neuroendocrine Tumor

4. Gastroenteropancreatic Neuroendocrine Tumor Patient Share (%) Overview at a Glance

5. Gastroenteropancreatic Neuroendocrine Tumor Market Overview at a Glance

6. Gastroenteropancreatic Neuroendocrine Tumor Disease Background and Overview

7. Gastroenteropancreatic Neuroendocrine Tumor Epidemiology and Patient Population

8. Country-Specific Patient Population of Gastroenteropancreatic Neuroendocrine Tumor 

9. Gastroenteropancreatic Neuroendocrine Tumor Current Treatment and Medical Practices

10. Gastroenteropancreatic Neuroendocrine Tumor Unmet Needs

11. Gastroenteropancreatic Neuroendocrine Tumor Emerging Therapies

12. Gastroenteropancreatic Neuroendocrine Tumor Market Outlook

13. Country-Wise Gastroenteropancreatic Neuroendocrine Tumor Market Analysis (2020–2034)

14. Gastroenteropancreatic Neuroendocrine Tumor Market Access and Reimbursement of Therapies

15. Gastroenteropancreatic Neuroendocrine Tumor Market Drivers

16. Gastroenteropancreatic Neuroendocrine Tumor Market Barriers

17.  Gastroenteropancreatic Neuroendocrine Tumor Appendix

18. Gastroenteropancreatic Neuroendocrine Tumor Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/